Novel Adjuvants to Enhance the Immunogenicity of a Dengue Vaccine

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-15-C-0119
Agency Tracking Number: A151-052-0878
Amount: $99,888.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: A15-052
Solicitation Number: 2015.1
Timeline
Solicitation Year: 2015
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-09-21
Award End Date (Contract End Date): 2016-04-20
Small Business Information
99-193 AIEA HEIGHTS DRIVE, SUITE 200, AIEA, HI, 96701
DUNS: 113226823
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 David Clements
 Director of Molecular Biology
 (808) 792-1303
 dclements@hibiotech.com
Business Contact
 Laurence Knutson
Title: Mr.
Phone: (808) 792-1394
Email: lknutson@hibiotech.com
Research Institution
N/A
Abstract
Dengue virus (DENV) is a mosquito-borne flavivirus that poses a tremendous public health threat throughout the world. The U.S. military has also been challenged by dengue for over a hundred years and the pursuit of an effective DENV vaccine is a high priority for the Department of Defense (DoD). Despite over 70 years of efforts, there is still no registered dengue vaccine. While significant progress has been made in the last decade, challenges still remain. To help enhance development of a DENV vaccine candidate there two key areas that need to be addressed; robust immunogenicity, both antibody titers and durability, and shorting the duration of immunization schedule. This application is directed at demonstrating the enhanced immunogenicity of formulations comprised of an inactivated DENV and novel adjuvants. The use of novel adjuvants with the potential for clinical use will help accelerate the development of an enhanced inactivated DENV vaccine. For the first phase of this effort the technical objectives are to first screen and select formulations with robust immunogenicity and then to demonstrate protective efficacy in a lethal mouse challenge model. In this manner we will demonstrate the feasibility of developing an adjuvanted-inactivated dengue vaccine with enhanced and durable immune responses.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government